JPN Guidelines for the management of acute pancreatitis: diagnostic criteria for acute pancreatitis

MASARU KOIZUMI¹, TADAHIRO TAKADA²,*, YOSHIFUMI KAWARADA¹, KOICHI HIRATA¹, TOSHIHIKO MAYUMI⁵, MASAHIRO YOSHIDA², MIHO SEKIMOTO⁶, MASAKI HIROTA⁷, YASUTOSHI KIMURA⁴, KAZUNORI TAKEDA⁸, SHUJI ISAJI⁹, MAKOTO OTSUBI¹⁰,*, and SEIKI MATSUNO¹¹,***

¹Ohara Medical Center Hospital, 33 Kamata aza Nakae, Fukushima 960-0195, Japan
²Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
³Ueno Municipal Hospital, Mie, Japan
⁴First Department of Surgery, Sapporo Medical University School of Medicine, Hokkaido, Japan
⁵Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan
⁶Department of Healthcare Economics and Quality Management, Kyoto University Graduate School of Medicine, Kyoto, Japan
⁷Department of Gastroenterological Surgery, Kumamoto University Graduate School of Medical Science, Kumamoto, Japan
⁸Department of Surgery, National Hospital Organization Sendai Medical Center, Sendai, Japan
⁹Department of Hepatobiliary Pancreatic Surgery and Breast Surgery, Mie University Graduate School of Medicine, Mie, Japan
¹⁰Department of Gastroenterology and Metabolism, University of Occupational and Environmental Health, Japan, School of Medicine, Kitakyushu, Japan
¹¹Division of Gastroenterological Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan

Abstract
The currently used diagnostic criteria for acute pancreatitis in Japan are presentation with at least two of the following three manifestations: (1) acute abdominal pain and tenderness in the upper abdomen; (2) elevated levels of pancreatic enzyme in the blood, urine, or ascitic fluid; and (3) abnormal imaging findings in the pancreas associated with acute pancreatitis. When a diagnosis is made on this basis, other pancreatic diseases and acute abdomen can be ruled out. The purpose of this article is to review the conventional criteria and, in particular, the various methods of diagnosis based on pancreatic enzyme values, with the aim of improving the quality of diagnosis of acute pancreatitis and formulating common internationally agreed criteria. The review considers the following recommendations:

— Better even than the total blood amylase level, the blood lipase level is the best pancreatic enzyme for the diagnosis of acute pancreatitis and its differentiation from other diseases.
— A pivotal factor in the diagnosis of acute pancreatitis is identifying an increase in pancreatic enzymes in the blood.
— Ultrasoundography (US) is also one of the procedures that should be performed in all patients with suspected acute pancreatitis.
— Magnetic resonance imaging (MRI) is one of the most important imaging procedures for diagnosing acute pancreatitis and its intraabdominal complications.
— Computed tomography (CT) is also one of the most important imaging procedures for diagnosing acute pancreatitis and its intraabdominal complications. CT should be performed when a diagnosis of acute pancreatitis cannot be established on the basis of the clinical findings, results of blood and urine tests, or US, or when the etiology of the pancreatitis is unknown.
— When acute pancreatitis is suspected, chest and abdominal X-ray examinations should be performed to determine whether any abnormal findings caused by acute pancreatitis are present.
— Because the etiology of acute pancreatitis can have a crucial influence on both the treatment policy and severity assessment, it should be evaluated promptly and accurately. It is particularly important to differentiate between gallstone-induced acute pancreatitis, which requires treatment of the biliary system, and alcohol-induced acute pancreatitis, which requires a different form of treatment.

Key words Acute pancreatitis · Criteria for diagnosing acute pancreatitis · Laboratory diagnosis · Computed tomography

Offprint requests to: M. Koizumi
*President, Japanese Society of Emergency Abdominal Medicine; President, Japanese Society of Hepato-Biliary-Pancreatic Surgery; President, Asian-Pacific Hepato-Pancreato-Biliary Association
**Chairman, Intractable Pancreatic Disease Investigation and Research Group of the Japanese Ministry of Health, Labour, and Welfare
***President, Japan Pancreas Society
Clinical questions

CQ1. Are clinical symptoms and signs useful in diagnosing acute pancreatitis?
CQ2. Which pancreatic enzymes should be measured to diagnose acute pancreatitis?
CQ3. What is the optimal examination for diagnosing acute pancreatitis?
CQ4. Is US effective in diagnosing acute pancreatitis?
CQ5. Is MRI effective in diagnosing acute pancreatitis?
CQ6. Is CT effective in diagnosing acute pancreatitis?
CQ7. Are plain X-ray examinations useful in diagnosing acute pancreatitis?
CQ8. Is the etiology of a specific case of acute pancreatitis necessary for its diagnosis?

Introduction

The diagnosis of acute pancreatitis has been based on the clinical manifestations and results of blood-biochemistry tests, but there are few common criteria that strictly specify the parameters to be used in diagnosis.

The criteria currently used to diagnose acute pancreatitis in Japan were originally developed by the Research Group for Intractable Diseases and Refractory Pancreatic Diseases, which was sponsored by the Japanese Ministry of Health and Welfare (now the Japanese Ministry of Health, Labour, and Welfare). The Research Group states that acute pancreatitis should be diagnosed if the patient presents with at least two of the following three criteria: (1) acute abdominal pain and tenderness in the upper abdomen; (2) elevated levels of pancreatic enzymes in blood, urine, or ascitic fluid; and (3) the presence of abnormal imaging findings in the pancreas that are associated with acute pancreatitis. When a diagnosis is made on this basis, other pancreatic diseases and acute abdomen can be ruled out.

In Japan, many surgeons and physicians specializing in digestive system diseases and emergency medicine are familiar with abdominal ultrasonography (US) and perform it routinely. Magnetic resonance imaging (MRI) is less popular than X-rays or computed tomography (CT) scanning and is not a routine procedure in emergency examinations for abdominal diseases.

The purpose of this article is to review the conventional criteria and, in particular, the various methods of diagnosis based on pancreatic enzyme values, with the aim of improving the quality of the diagnosis of acute pancreatitis and of formulating common, internationally agreed upon criteria.

Diagnostic criteria

Clinical symptoms and signs

| Clinical question (CQ) 1. Are clinical symptoms and signs useful in diagnosing acute pancreatitis? |
| --- |
| It is essential to interview all patients (including those with consciousness disorders or who are in a state of shock), take their medical histories, and perform a physical examination (Recommendation A) |

Abdominal pain, pain radiating to the back, anorexia, fever, nausea and vomiting, and decreased bowel sounds are frequent manifestations of acute pancreatitis (Tables 1 and 2) (Level 4). However, these features are not specific to acute pancreatitis, and when a patient presents with these manifestations, acute pancreatitis must be differentiated from other acute abdominal diseases. Acute pancreatitis accounts for 2% to 3% of all acute abdominal diseases (Level 2b, unknown) and in a very few patients there is no abdominal pain (Level 2b).

Table 1. Symptoms and signs of acute pancreatitis

| Symptoms and signs\(^a\) (%) | Symptoms and signs\(^b\) (%) |
| --- | --- |
| Abdominal pain | 90 | Abdominal pain | 95 |
| Abdominal muscular rigidity | 80 | Pain radiating to the back | 50 |
| Fever | 80 | Anorexia | 85 |
| Nausea, vomiting | 70 | Nausea, vomiting | 75 |
| Meteorism | 60 | Decreased bowel sounds | 60 |
| Ileus, subileus | 55 | Fever | 60 |
| Jaundice | 30 | Abdominal guarding | 50 |
| Shock | 20 | Shock | 15 |
| Neurological symptoms | 10 | Jaundice | 15 |
|  |  | Hematoemesis | 10 |

\(^a\) Adapted from Malfertheiner P. and Kemmer T.P.\(^1\) 
\(^b\) Adapted from Corsetti and Arvan\(^2\)
Acute pancreatitis is sometimes manifested by discoloration of the skin, such as Grey Turner’s sign (on the lateral abdominal wall), Cullen’s sign (around the navel), and Fox’s sign (over the lower portion of the inguinal ligament). However, because these signs appear in only 3% (Level 2b) of patients, and because they are also observed in patients with other diseases (Level 4) and are often seen 48 to 72 h after the onset of pancreatitis, their diagnostic significance is low.

**Blood and urine tests**

**Blood lipase**

CQ2. Which pancreatic enzymes should be measured to diagnose acute pancreatitis?

*When making a diagnosis of acute pancreatitis or a differential diagnosis from other diseases, the blood lipase level is the best pancreatic enzyme parameter, even better than the total blood amylase level (Recommendation A)*

Comparisons of measurements of various pancreatic enzymes to detect the presence of acute pancreatitis (Level 2a) have shown that the blood lipase level is almost as sensitive as the total blood amylase level and has better specificity (Tables 3 and 4).9,10

According to Apple et al.,8 the sensitivity and specificity of blood lipase in the diagnosis of acute pancreatitis are 85% to 100% and 84.7% to 99.0% (Level 2a), respectively. The blood lipase value is more sensitive than blood amylase (Levels 2b-4) and provides diagnostic capability similar to that of blood P-amylase (Level 2b).13 Blood lipase is considered a valuable diagnostic tool, because abnormally high values persist for longer than abnormal blood amylase levels (Level 2b),14 and it is more sensitive in terms of detecting the presence of acute alcohol-induced pancreatitis. The combined use of blood amylase and blood lipase levels (Level 2a) does not facilitate the diagnosis of acute pancreatitis.

The above findings lead to the conclusion that the blood lipase level is an important indicator in the diagnosis of acute pancreatitis and that the measurement of the blood lipase level should be given top priority. Measurement of the lipase level is of primary importance when the blood amylase level of a patient suspected of having acute pancreatitis is normal.

**Blood amylase (blood total amylase)**

CQ3. What is the optimal examination for diagnosing acute pancreatitis?

*Identifying an increase in the level of pancreatic enzymes in the blood is a pivotal factor in the diagnosis of acute pancreatitis (Recommendation A)*

When the cutoff blood amylase level is set at the upper limit of normal, it has a sensitivity of 91.7% to 100% and a specificity of 71.6% to 97.6% for the diagnosis of acute pancreatitis. If the cutoff level is set higher, specificity

---

**Table 2. Symptoms and signs at onset of acute pancreatitis**

| Symptoms and signs                        | No. of cases | (%)  |
|------------------------------------------|--------------|------|
| Upper abdominal pain                     | 1150         | 95%  |
| Nausea–vomiting                          | 436          | 36%  |
| Pain radiating to the back               | 262          | 22%  |
| Anorexia                                 | 93           | 8%   |
| Meteorism                                | 85           | 7%   |
| Diarrhea–soft stool                      | 44           | 4%   |
| Fever–chill                              | 12           | 1%   |
| Loss of consciousness                    | 9            | 1%   |
| General fatigue                          | 7            | 1%   |

aPresented by the Intractable Pancreatic Disease Investigation and Research Group of the Japanese Ministry of Health and Welfare (JMHW) in 2000

**Table 3. Comparison of diagnostic tests for acute pancreatitis**

|               | Total amylase | Lipase | Pancreatic amylase |
|---------------|---------------|--------|--------------------|
| Sensitivity   | Very good (95%–100%) | Very good (90%–100%) | Good (84%–100%) |
| Specificity   | Low; (70%); influenced by cutoff level | Very good (99%); at upper limit of normal | Good (40%–97%); influenced by cutoff level |
| Positive predictive value (PPV) | Very low (15%–72%) | Very good (90%) | 50%–96% |
| Negative predictive value (NPV) | 97%–100% | 95%–100% | 70%–100% |
| Reliability   | Good          | Good   | Poor               |

Adapted from Agarwal et al.9

**Table 4. Sensitivity and specificity of amylase and other pancreatic enzymes**

|                      | Sensitivity (%) | Specificity (%) |
|----------------------|-----------------|-----------------|
| Total amylase        | 67–100          | 85–98           |
| Pancreatic amylase   | 67–100          | 83–98           |
| Lipase               | 82–100          | 82–100          |
| Trypsin              | 89–100          | 79–83           |
| Elastase-1           | 97–100          | 79–96           |

Adapted from Thomson et al.10
improves, but sensitivity declines. When the cutoff level is set at 1000 IU/l, specificity improves to 100%, but sensitivity declines to 60.9% (Levels 2a-4; Table 5).9,11,16-19 Sensitivity declines because (1) the blood amylase level does not rise as much in many patients with chronic alcoholic pancreatitis with acute exacerbations as it does in patients with acute pancreatitis (Level 2b)12,20 and (2) since the elevated blood amylase level declines almost immediately and is maintained for a shorter time than are other elevated pancreatic enzyme levels, the level must be measured soon after the onset (Levels 3b-4).21,22 The blood amylase level seldom rises in acute pancreatitis caused by hyperlipidemia (Level 3b).23 Because many other diseases besides pancreatitis are associated with hyperamylasemia (Table 6; Level 2a),8 it is necessary to measure extrapancreatic enzymes with high specificity for pancreatitis in order to make a proper differential diagnosis of pancreatitis. If the blood

Table 5. Sensitivity, specificity, PPV, and NPV for serum amylase, P-isoamylase, and lipase assays

| Author       | Year | Methodology          | Upper normal limit (IU/l) | Cutoff value (IU/l) | Sensitivity | Specificity | PPV  | NPV  |
|--------------|------|----------------------|---------------------------|--------------------|-------------|-------------|------|------|
| Amylase      | Pace16 1985 Phadebas | 300                    | 300                       | 100.0              | 71.6        | 15.6        | 100  |
|              | Steinberg17 1985 Phadebas | 326                    | 326                       | 94.9               | 86.0        | 75.5        | 97.4 |
|              | Ventruci18 1986 Phadebas | 377                    | 377                       | 91.7               | 77.8        | 35.5        | 98.6 |
|              | Thomson18 1987 Phadebas | 316                    | 316                       | 95.6               | 97.6        | 91.7        | 98.8 |
|              | Ventruci19 1982 Cellulose electrophoresis | 52                     | 52                        | 92.3               | 85.1        | 73.5        | 96.1 |
|              | Ventrucci18 1986 Phadebas | 181                    | 181                       | 92.3               | 85.1        | 73.5        | 96.1 |
|              | Pace18 1985 Phadebas | 375                    | 375                       | 84.0               | 96.5        | 91.7        | 93.3 |
|              | Ventruci18 1986 Phadebas | 120                    | 225                       | 100.0              | 48.9        | 17.9        | 100  |
| P-amylase    | Koehler19 1988 Cellulose electrophoresis | 220                    | 220                       | 100.0              | 84.4        | 46.2        | 100.0 |
|              | Steinberg17 1985 Wheat protein inhibitor | 72                     | 75                        | 86.5               | 99.0        | 97.0        | 95.1 |
|              | Ventrucci18 1986 Phadebas | 62                     | 62                        | 91.7               | 84.7        | 42.3        | 98.9 |
| Lipase       | Steinberg17 1985 Turbidimetric | 68                     | 68                        | 100.0              | 96.0        | 85.0        | 100.0 |
|              | Ventruci18 1986 ELISA | 68                     | 68                        | 100.0              | 96.0        | 85.0        | 100.0 |

PPV, positive predictive value; NPV, negative predictive value
Adapted from Agarwal et al.9

Table 6. Conditions associated with elevation of serum amylase

| Pancreatic diseases | Extrapancreatic neoplasms | Miscellaneous |
|---------------------|---------------------------|---------------|
| Pancreatitis        | Solid tumors of ovary, prostate, lung, esophagus, breast, thymus | Renal failure |
| Complications of pancreatitis (pseudocyst, abscess) | Multiple myeloma | Renal transplant |
| Trauma (including surgery and ERCP) | Pheochromocytoma | Macroamylase |
| Ductal obstruction | Miscellaneous | Burns |
| Pancreatic carcinoma | Miscellaneous | Acidosis (ketotic and nonketotic) |
| Cystic fibrosis (early) | Miscellaneous | Pregnancy |

Salivary diseases

| Salivary diseases | Extrapancreatic neoplasms | Miscellaneous |
|-------------------|---------------------------|---------------|
| Infection (mumps) | Solid tumors of ovary, prostate, lung, esophagus, breast, thymus | Renal failure |
| Trauma (including surgery) | Multiple myeloma | Renal transplant |
| Radiation | Pheochromocytoma | Macroamylase |
| Ductal obstruction | Miscellaneous | Burns |

Gastrointestinal diseases

| Gastrointestinal diseases | Extrapancreatic neoplasms | Miscellaneous |
|---------------------------|---------------------------|---------------|
| Perforated/penetrating peptic ulcer | Solid tumors of ovary, prostate, lung, esophagus, breast, thymus | Renal failure |
| Perforated/obstructed bowel | Multiple myeloma | Renal transplant |
| Mesenteric infarction | Pheochromocytoma | Macroamylase |
| Appendicitis | Miscellaneous | Burns |
| Liver disease (hepatitis, cirrhosis) | Miscellaneous | Acidosis (ketotic and nonketotic) |

Gynecologic diseases

| Gynecologic diseases | Extrapancreatic neoplasms | Miscellaneous |
|----------------------|---------------------------|---------------|
| Ruptured ectopic pregnancy | Solid tumors of ovary, prostate, lung, esophagus, breast, thymus | Renal failure |
| Ovarian or fallopian cysts | Multiple myeloma | Renal transplant |
| Pelvic inflammatory disease | Pheochromocytoma | Macroamylase |

Adapted from Apple et al.8
enzyme value and/or imaging findings do not allow for a diagnosis of acute pancreatitis in a patient with ascites, the amylase level in the ascitic fluid may be useful in making the diagnosis. However, it is not usually very useful, because the amylase level in the ascitic fluid sometimes increases in other diseases, including alimentary tract perforation.

P-amylase (amylase isozyme)

The blood P-amylase level is considered useful in the differential diagnosis of hyperamylasemia, and, while one report claimed it could identify 83% of patients (19/23) with hyperamylasemia independent of pancreatic disease (Level 4), others suggest a capability of only 20% to 44% (Levels 3b-4). There is a report describing the blood P-amylase level as a useful indicator, because the abnormally high level is maintained for longer than the abnormal blood amylase levels in acute pancreatitis (Levels 3b), but another report showed that the blood P-amylase level did not improve sensitivity or specificity (Level 2b). The diagnostic value of the P-amylase level for acute pancreatitis requires further study.

Blood elastase-1 and other pancreatic enzymes

Clinically measurable extrapancreatic enzymes can be roughly classified into blood and urine amylase, P-amylase (amylase isozyme), and serum lipase, whose enzymatic activity is measured by an enzyme-chemical method; and serum elastase-1, serum trypsin, and serum phospholipase A2 (PLA2), whose antigen levels are measured immunologically. Because the immunological measurements require a lot of time, it is difficult to use them as a routine procedure for the diagnosis of acute pancreatitis. A latex agglutination method has enabled the rapid, convenient measurement of the serum elastase-1 level. Elastase-1 has the advantage of maintaining an abnormally high value for longer than the levels of other pancreatic enzymes (Level 3b), although the ability to diagnose or assess the severity of acute pancreatitis (Level 2b) was not improved by the combined use of the serum elastase-1 and blood amylase levels.

Trypsin is a key enzyme present at the onset of acute pancreatitis, but its activity cannot be measured, because it is too rapidly inactivated by protease inhibitors in the blood, and therefore the quantity of the antigen should be measured immunologically. Blood trypsin has high sensitivity for the diagnosis of acute pancreatitis (Level 2b). The blood PLA2 level rises markedly in acute pancreatitis and is correlated with the severity (Levels 3b-4). Qualitative evaluation of urine trypsinogen-2 with test paper to determine its rate of positivity in acute pancreatitis has shown that it has a diagnostic ability similar to that of lipase, and it is expected to be useful in early diagnosis (Levels 3b-4).

Imaging examinations

Ultrasonography (US)

| CQ4. Is US effective in diagnosing acute pancreatitis? |
|---------------------------------------------------------|
| Ultrasonography (US) is one of the diagnostic procedures that should be performed first in all patients suspected of having acute pancreatitis (Recommendation A) |
| Ultrasonography (US) is capable of identifying pancreatic enlargement and inflammatory changes near the pancreas, and it may be useful in diagnosing acute pancreatitis. Although, in severe cases, visualization of the pancreas and peripancreatic tissue may be impaired by gas in the intestinal tract (Levels 1b-2b), the visualization rate is 62% to 90% for the pancreas, 100% for the peripancreatic tissue in the anterior paranephric cavity, 90% in the cavity of the lesser omentum, and 65% in the mesentery (Levels 1b-2b). Ultrasoundography may also visualize abnormal findings associated with the etiology and morbidity of acute pancreatitis, such as ascites, gallstones, and cholangiectasis. It is particularly important to check for the presence of cholecholithiasis and cholangiectasis when judging whether endoscopic sphincterotomy for gallstone pancreatitis is required. It is desirable to examine patients repeatedly, using US, even when no gallstones are detected by the initial examination. US is also useful for screening for comorbidities such as aneurysms. |

Magnetic resonance imaging (MRI)

| CQ5. Is MRI effective in diagnosing acute pancreatitis? |
|---------------------------------------------------------|
| MRI is one of the most important imaging procedures for the diagnosis of acute pancreatitis and its intraabdominal complications (Recommendation B) |
| MRI scanning visualizes pancreatic enlargement and the inflammatory changes around the pancreas (Level 2c) and can distinguish the intestinal tract from the necrotic part of the pancreas. Gadolinium-DTPA (Gd-DTPA)-enhanced MRI can visualize foci of pancreatic necrosis (Level 2b). MRI accurately depicts the state of necrosis, the main pancreatic ducts, and the extent of inflammation, and it has more value than CT (Levels 2b-3c). MRI scanning has the advantage of no X-ray |
exposure. However, because MRI takes much longer than CT scanning and requires the removal of all metal objects (such as respirators and transfusion pumps) before the examination, it is not routinely used to diagnose acute pancreatitis in Japan, where the system for MRI use is not yet adequate. However, magnetic resonance cholangiopancreatography (MRCP) is often required to identify the etiology of acute pancreatitis, such as cholecholithiasis (Level 4)\cite{41} and abnormal pancreatico-choledochal junction (abnormal junction of the pancreato-biliary ducts; Level 4).\cite{42} MRI scanning can be performed earlier than CT, because it requires no operation of the duodenal papilla and there is no risk of aggravating acute pancreatitis. Although MRCP is noninvasive, it has the disadvantages of less clear imaging than endoscopic retrograde cholangiopancreatography (ERCP) and impaired visualization due to peripancreatic fluid collection.

**Computed tomography (CT)**

**CQ6. Is CT effective in diagnosing acute pancreatitis?**

*CT is one of the most important imaging procedures for the diagnosis of acute pancreatitis and its intraabdominal complications. CT should be performed when the diagnosis of acute pancreatitis cannot be established on the basis of the clinical findings and the results of blood and urine tests and US, or when the etiology of the pancreatitis is unknown (Recommendation B)*

CT is unaffected by the adipose tissue in the abdominal wall and inside the abdominal cavity, and it provides clear local images (Level 1b).\cite{34} CT findings useful for the diagnosis of acute pancreatitis include an enlarged pancreas, inflammatory change around the pancreas, fluid collections, uneven density of the pancreatic parenchyma, and traumatic disruption of the pancreas (Figs. 1, 2, and 3). Gas patterns visualized inside and around the pancreas are often due to fistula formation with the intestinal tract and infection by gas-forming anaerobes (Level 1c).\cite{36}

CT scanning allows for the differentiation of acute pancreatitis from other intraabdominal diseases, such as perforation caused by a gastroduodenal ulcer, and it allows the diagnosis of comorbidities in intra-abdominal organs and complications of pancreatitis; it is also an important procedure for assessing the severity of

*Fig. 1. Plain computed tomography (CT) shows enlargement of the pancreatic body and tail and poorly defined margins of the pancreatic body*

*Fig. 2. Plain CT shows enlarged pancreas, associated haziness, and increased density of peripancreatic fat*

*Fig. 3. Contrast-enhanced CT shows low-density region of the pancreatic tail and fluid in the left anterior pararenal space*
acute pancreatitis and selecting a treatment plan. CT scanning is especially needed in severe acute pancreatitis, where adequate information cannot be obtained by US because of abdominal pain and the complication of ileus.

Plain X-rays

CQ7. Are plain X-ray examinations useful in diagnosing acute pancreatitis?

When acute pancreatitis is suspected, chest and abdominal X-ray examinations should be performed to check for the presence of any abnormal findings caused by acute pancreatitis (Recommendation A)

Abdominal X-ray examinations in acute pancreatitis visualize ileus, localized sentinel loop signs in the left upper abdomen, enlarged duodenal loops and gas collections, colon cutoff signs in the right colon, retroperitoneal gas collection, calcified gallstones, and pancreatolithiasis.

Chest X-rays visualize pleural effusion, acute respiratory distress syndrome (ARDS), and pneumonia. None of these findings, however, are specific enough to make a diagnosis of acute pancreatitis (level 4). X-ray examinations are necessary, however, to evaluate the clinical course of acute pancreatitis and to differentiate acute pancreatitis from other diseases, such as alimentary tract perforation.

Search for the etiology

CQ8. Is the etiology of a specific case of acute pancreatitis necessary for its diagnosis?

The etiology of acute pancreatitis may have a crucial impact on treatment policy as well as the severity assessment, and it should be determined promptly and accurately. It is particularly important to differentiate acute gallstone pancreatitis, which requires treatment of the biliary system, from acute alcoholic pancreatitis, which requires a different form of treatment (Recommendation A)

Abdominal US should be performed immediately with the start of treatment in order to detect the presence of abnormal findings associated with the etiology of acute pancreatitis, such as gallstones or dilated bile ducts.

If acute gallstone pancreatitis is accompanied by jaundice, liver disorders, or cholangiectasis, and where cholecholithiasis is suspected, ERCP is required immediately after the onset, but it should be performed only for the purpose of endoscopic treatment, sphincterotomy, and biliary drainage.

ERCP should be performed in patients with acute gallstone pancreatitis who are strongly suspected of having gallstones, but only for the purposes of determining etiology and performing endoscopic treatment. ERCP has several risk factors (level 2b). Because ERCP may exacerbate the inflammation at the onset of acute pancreatitis, it should be performed only for limited indications. The guidelines of the British Society of Gastroenterology recommend the performance of ERCP in patients with jaundice, liver disorders, or cholangiectasis, and in those who are strongly suspected of having cholecholithiasis and have had repeated attacks of pancreatitis. Patients with repeated attacks of pancreatitis may have anatomical disorders, such as malfusion of the biliary ducts or abnormal junction of the pancreaticobiliary ducts, or they may have a tumor or choledocholithiasis. Because such features are difficult to visualize using other procedures, it is recommended that ERCP be performed as a standby procedure to differentiate the etiology of these disorders and complications.

There is a report claiming that endoscopic US (EUS) can identify cholecholithiasis in 77.8% of patients whose etiology has not been identified by blood tests, US, and CT scanning (level 2b). EUS is indicated in any patient with severe acute pancreatitis in whom choledocholithiasis is strongly suspected, but it should be performed only after adequate evaluation of the patient’s general condition. ERCP should be performed without delay. Cases in which cholecholithiasis cannot be diagnosed by extracorporeal US are a good indication for EUS, after the attack subsides.

References

1. Mallortheiner P, Kemmer TP. Clinical picture and diagnosis of acute pancreatitis. Hepatogastroenterology 1991;38:97–100.
2. Corsetti JP, Arvan DA. Acute pancreatitis. In: Black ER, Bordley DR, Tape TG, Panzer RJ, editors. Diagnostic strategies for common medical problems. 2nd ed. Philadelphia: American College of Physicians; 1999. p. 205.
3. de Dombal F. Acute abdominal pain. An OMGE survey. Scand J Gastroenterol 56 (Suppl) 1979;14:29–43.
4. de Dombal FT. Diagnosis of acute abdominal pain. 2nd ed. London: Churchill Livingstone; 1991. p. 19–30.
5. Read G, Braganza JM, Howat HT. Pancreatitis: a retrospective study. Gut 1976;17:945–52.
6. Dickson AP, Imrie CW. The incidence and prognosis of body wall ecchymosis in acute pancreatitis. Surg Gynecol Obstet 1984;159:343–7.
7. Bern J, Bradley EL III. Subcutaneous manifestations of severe acute pancreatitis. Pancreas 1998;16:551–5.
8. Apple F, Benson P, Preese L, Eastep S, Bilodeau L, Heiler G. Lipase and pancreatic amylase activities in tissues and in patients with hyperamylasemia. Am J Clin Pathol 1991;96:610–4.
9. Agarwal N, Pitchumoni CS, Sivaprasad AV. Evaluating tests for acute pancreatitis. Am J Gastroenterol 1990;85:356–66.
30. Schroder T, Lempinen M, Kivilaakso E, Nikki P. Serum phospho-

29. Ventrucci M, Pezzilli R, Gullo L, Plate L, Sprovieri G, Barbara L.

28. Millson CE, Charles K, Poon P, Macfie J, Mitchell CJ. A pro-

27. Flamion B, Delhaye M, Horanyi Z, Delange A, Demanet H,

26. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

24. Swensson EE, King ME, Malekpour A, Maull KI. Serum amylase

23. Vissers RJ, Abu-Laban RB, McHugh DF. Amylase and lipase

22. Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin

21. Ventrucci M, Pezzilli R, Naldoni P, Plate L, Baldoni F, Gullo L,

20. Eckfeldt JH, Kolars JC, Elson MK, Shafer RB, Levitt MD. Serum

19. Clavien PA, Robert J, Meyer P, Burson LC, Borrero E. Amylase

18. Koehler DF, Eckfeldt JH, Levitt MD. Diagnostic value of routine

17. Ventrucci M, Pezzilli R, Naldoni P, Montone L, Gullo L. A rapid

16. Steinberg WM, Goldstein SS, Davis ND, Shamma’a J, Anderson

15. Pace BW, Bank S, Wise L, Burson LC, Borrero E. Amylase

14. Gumaste V, Dave P, Sereny G. Serum lipase: a better test to

13. Orebaugh SL. Normal amylase levels in the presentation of acute

12. Levitt MD, Johnson SG. Is the CAm/CCr ratio of value for the

11. Nordestgaard AG, Wilson SE, Williams RA. Correlation of

32. M. Koizumi et al.: Diagnostic criteria for acute pancreatitis

26. Kemppainen EA, Hedstrom JI, Puolakkainen PA, Sainio VS,

25. Chen YT, Chen CC, Wang SS, Chang FY, Lee SD. Rapid urinary

24. Silverstein W, Isikoff MB, Hill MC, Barkin J. Diagnostic imaging

23. Hirota M, Kimura Y, Ishiko T, Beppu T, Yamashita Y, Ogawa M.

22. Hirohashi S, Hirohashi R, Uchida H, Akira M, Itoh T, Haku E, et

21. Lomas DJ, Bearcroft PWP, Gimson AE. MR cholangiopancreato-

20. Arvanitakis M, Delhaye M, De Maertelaere V, Bali M, Winant C,

19. Dervenis C, Johnson CD, Bassi C, Bradley E, Imrie CW, Bottle

18. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

17. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

16. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

15. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

14. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

13. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

12. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

11. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

10. Thomson HJ, Obckpa, PO, Smith AN, Brydon WG. Diagnosis of

9. Nordestgaard AG, Wilson SE, Williams RA. Correlation of

8. Millson CE, Charles K, Poon P, Macfie J, Mitchell CJ. A pro-

7. Flamion B, Delhaye M, Horanyi Z, Delange A, Demanet H,

6. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

5. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

4. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

3. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

2. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

1. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

M. Koizumi et al.: Diagnostic criteria for acute pancreatitis

31. Nishijima J, Okamoto M, Ogawa M, Kosaki G, Yamano T. Purification and characterization of human pancreatic phospholi-

30. Schroder T, Lempinen M, Kivilaakso E, Nikki P. Serum phospho-

29. Ventrucci M, Pezzilli R, Gullo L, Plate L, Sprovieri G, Barbara L.

28. Millson CE, Charles K, Poon P, Macfie J, Mitchell CJ. A pro-

27. Flamion B, Delhaye M, Horanyi Z, Delange A, Demanet H,

26. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

25. Chen YT, Chen CC, Wang SS, Chang FY, Lee SD. Rapid urinary

24. Silverstein W, Isikoff MB, Hill MC, Barkin J. Diagnostic imaging

23. Hirota M, Kimura Y, Ishiko T, Beppu T, Yamashita Y, Ogawa M.

22. Hirohashi S, Hirohashi R, Uchida H, Akira M, Itoh T, Haku E, et

21. Lomas DJ, Bearcroft PWP, Gimson AE. MR cholangiopancreato-

20. Arvanitakis M, Delhaye M, De Maertelaere V, Bali M, Winant C,

19. Dervenis C, Johnson CD, Bassi C, Bradley E, Imrie CW, Bottle

18. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

17. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

16. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

15. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

14. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

13. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

12. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

11. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De

10. Thomson HJ, Obckpa, PO, Smith AN, Brydon WG. Diagnosis of

9. Nordestgaard AG, Wilson SE, Williams RA. Correlation of

8. Millson CE, Charles K, Poon P, Macfie J, Mitchell CJ. A pro-

7. Flamion B, Delhaye M, Horanyi Z, Delange A, Demanet H,

6. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

5. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

4. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

3. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

2. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and

1. Buchler M, Malfertheiner P, Uhl W, Beger HG. Diagnostic and